Podiatrist Loses DEA Registration Over State License Issue
Published Date: 6/24/2026
Notice
Summary
Irina Gross, a podiatrist from Ohio, lost her DEA registration because she no longer has the state permission to handle controlled substances. She didn’t ask for a hearing, so the DEA canceled her registration by default. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately, impacting her medical practice and patients.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Named Podiatrist
The Drug Enforcement Administration revoked DEA Certificate of Registration No. FG2593487 issued to Irina Gross, D.P.M., because she no longer has state authority to handle controlled substances. The revocation is effective July 24, 2026; her Ohio DPM and RCP licenses were suspended effective June 11, 2025 and are recorded as permanently revoked in Ohio online records.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-19538, Bulk Manufacturer of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.
Cambridge Isotope Laboratories wants to make a lot of a special drug called Tetrahydrocannabinols for testing purposes. People who already make or use this drug can share their thoughts by December 23, 2026, and ask for a hearing by November 23, 2026. This move could help scientists get better testing materials without changing how the drug is used.
2026-19542, Bulk Manufacturer of Controlled Substances Application: Cayman Chemical Company
Cayman Chemical Company wants to become an official bulk maker of some powerful controlled substances, mostly in Schedule I. This means they’ll be able to produce these drugs in large amounts for research or medical use. If you have thoughts or objections, you’ve got until November 23, 2026, to speak up online—no fees or money changes yet, just a chance to weigh in!
2026-19540, Importer of Controlled Substances Application: Fisher Clinical Services, Inc. (I)
Fisher Clinical Services, Inc. wants to become an official importer of certain controlled substances like marijuana and its extracts. This affects companies involved in drug manufacturing and importation, who can comment or request a hearing by October 26, 2026. No direct costs are mentioned, but this move could impact how these substances enter the U.S. market.
Previous / Next Documents
Previous: 2026-12649, Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee
The Department of Defense is holding a public meeting on June 22, 2026, to discuss updates to the Uniform Formulary, which affects military health beneficiaries and their medication options. This meeting will review recommendations that could change which medicines are covered, potentially impacting costs and access. Anyone interested can join by phone and share their thoughts, making it a great chance to have a say in military healthcare decisions.
Next: 2026-12651, Certain Frozen Fish Fillets From Vietnam; Determination
The U.S. International Trade Commission decided to keep the extra taxes on frozen fish fillets from Vietnam because removing them could hurt American fish businesses. This means importers will still pay these duties, helping protect U.S. jobs and companies. The decision was finalized in June 2026 and affects anyone buying or selling these fish fillets in the U.S.